Saturday - June 20, 2026

Spinocerebellar Ataxias Pipeline Gains Momentum with 10+ Emerging Therapies Across Clinical Development, Driven by Advances in Gene-Silencing and Regenerative Medicine

The Spinocerebellar Ataxias pipeline landscape is witnessing significant progress, fueled by increasing research into gene-targeted therapies, antisense oligonucleotides, stem cell-based approaches, and disease-modifying treatment strategies. Growing scientific understanding of the genetic mechanisms underlying Spinocerebellar Ataxias is encouraging the development of … Continue reading

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the HPV+ Recurrent/Metastatic Head and Neck Cancer … Continue reading

Urinary Tract Infections Pipeline Shows Strong Momentum as 38+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Urinary Tract Infections Pipeline Insight 2026” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in the Urinary Tract Infections pipeline landscape. It covers the Urinary Tract Infections Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Oncolytic Virus Cancer Therapy Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2026” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical … Continue reading

Eosinophilic Esophagitis Pipeline Shows Strong Momentum as 25+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insights 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading

Acromegaly Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Acromegaly Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acromegaly pipeline … Continue reading

Small Cell Lung Cancer Pipeline Shows Strong Momentum as 100+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading

Charcot Marie Tooth Pipeline Shows Strong Momentum as 13+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Charcot Marie Tooth Disease Pipeline Insight, 2026” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Charcot Marie Tooth Disease pipeline landscape. It covers the Charcot Marie Tooth pipeline drug profiles, including clinical and nonclinical stage … Continue reading